2023 World Conference on Lung Cancer (Posters)-EP12.01. Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure

EP12.01. Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure - PDF(Slides)

Back to course

Pdf Summary

This case report describes the efficacy of amivantamab in a patient with EGFR exon 20 insertion (Ex20ins) lung adenocarcinoma who had symptomatic pleural effusion after platinum doublet treatment failure. The patient initially had stage IVA NSCLC with EGFR Ex20ins and achieved a deep partial response including reduction of pleural effusion with amivantamab after progression on platinum doublet treatment. The patient showed a partial response to amivantamab, which was maintained for eight months. Amivantamab also seemed to have activity against symptomatic pleural effusion. The patient experienced mild toxicity, but it was manageable with prophylactic measures. This case report highlights the potential efficacy of amivantamab in treating NSCLC with EGFR Ex20ins, which is often difficult to treat. It suggests that amivantamab may be a valid treatment option and offers a window of opportunity for this patient population. The report emphasizes the fast and lasting response observed in this patient and mentions the additional value of amivantamab in addressing symptomatic pleural effusion. <br /><br />Overall, this case report adds to the growing body of evidence supporting the use of amivantamab in NSCLC patients with EGFR Ex20ins. It is important to note that this report is based on a single case, and more research is needed to establish the generalizability of these findings. However, this case provides valuable insights into the potential benefits of amivantamab in this specific patient population. References to other studies investigating amivantamab in NSCLC with EGFR Ex20ins are provided for further information. It is worth mentioning that the patient consented to the publication of their case in this congress.

Asset Subtitle

Javier Baena

Meta Tag

Speaker Javier Baena

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

amivantamab

EGFR exon 20 insertion

lung adenocarcinoma

pleural effusion

platinum doublet treatment

NSCLC

partial response

toxicity

prophylactic measures

treatment option